RESUMEN
BACKGROUND: Hydrarthrosis, which is associated with knee pain and limited range of motion, decreases the quality of life (QOL) of patients with osteoarthritis (OA). The Kampo medicine boiogito is prescribed for the treatment of knee OA with hydrarthrosis; however, its precise mechanisms of action remain unknown. The purposes of this study were to assess the pharmacological effects of boiogito and its mechanisms of action on joint effusion in rats with surgically induced OA. METHODS: A rat OA model was produced by transecting the anterior (cranial) cruciate ligament, medial collateral ligament, and medial meniscus in the right knee joints of 7-week-old female Wistar rats. The rats were given chow containing boiogito (1 or 2%) or indomethacin (0.002 %) for 4 weeks after surgical transection. Levels of interleukin-1ß (IL-1ß) and hyaluronic acid (HA) were measured by enzyme-linked immunosorbent assay. Knee joint pain was assessed using an incapacitance tester. Osmotic water permeability in cultured rabbit synovial cells was assessed using stopped-flow analysis. RESULTS: Increased synovial fluid volume and knee joint pain were observed in rats with surgically induced OA. In rats with OA, levels of IL-1ß and HA in the articular cavity were higher but concentration of HA in synovial fluid was lower than in sham-operated rats, suggesting excessive synovial fluid secretion. Administration of boiogito improved hydrarthrosis, IL-1ß, and HA concentrations and alleviated knee joint pain in rats with OA. Indomethacin reduced IL-1ß and knee joint pain but failed to improve hydrarthrosis or HA concentration in rats with OA. Osmotic water permeability in synovial cells, which is related to the function of the water channel aquaporin, was decreased by treatment with boiogito. CONCLUSION: Boiogito ameliorates the increased knee joint effusion in rats with OA by suppressing pro-inflammatory cytokine IL-1ß production in the articular cavity and regulating function of water transport in the synovium. The improvement of hydrarthrosis by boiogito results in the increased HA concentration in synovial fluid, thus reducing joint pain. Boiogito may be a clinically useful treatment of QOL in patients with OA with hydrarthrosis.
Asunto(s)
Hidrartrosis/tratamiento farmacológico , Medicina Kampo , Osteoartritis de la Rodilla/tratamiento farmacológico , Extractos Vegetales/administración & dosificación , Animales , Femenino , Humanos , Ácido Hialurónico/metabolismo , Hidrartrosis/metabolismo , Interleucina-1beta/metabolismo , Osteoartritis de la Rodilla/metabolismo , Plantas Medicinales , Conejos , Ratas , Ratas Wistar , Líquido Sinovial/metabolismoAsunto(s)
Hidrartrosis , Hidroxicloroquina/administración & dosificación , Articulación de la Rodilla , Antirreumáticos/administración & dosificación , Diagnóstico Diferencial , Femenino , Humanos , Hidrartrosis/diagnóstico , Hidrartrosis/tratamiento farmacológico , Hidrartrosis/fisiopatología , Articulación de la Rodilla/patología , Articulación de la Rodilla/fisiopatología , Persona de Mediana Edad , Recurrencia , Prevención Secundaria/métodos , Resultado del TratamientoRESUMEN
OBJECTIVES: Palindromic rheumatism (PR) is a type of acute arthritis or periarthritis characterized by recurrence, paroxysmal, or intermittent disease attacks and occasionally progresses to other types of rheumatic disease. PR patients who are anti-citrullinated protein antibodies (ACPA)-negative have a high prevalence of MEFV gene polymorphisms, and intermittent hydrarthrosis (IH) is also associated with MEFV polymorphisms. The purpose of this study was to evaluate the clinical characteristics of and autoinflammatory syndrome-associated gene polymorphisms in patients with PR and IH and to identify predictive factors for developing other rheumatic diseases. METHODS: Six PR patients (four females; median age at disease onset, 20.0 years; median age at evaluation, 47.0 years) were retrospectively evaluated for clinical features and polymorphisms in genes responsible for autoinflammatory diseases. RESULTS: All six patients fulfilled the diagnostic criteria for PR and showed clinical feature of IH. Two presented with recurrent fever. All six patients were negative for rheumatoid factor and ACPA and had normal articular X-ray findings. Among the six patients, MEFV gene polymorphisms known to cause FMF were identified in four, CIAS1 mutation was observed in one, and TNFRSFIA mutation was observed in one. Colchicine was effective in three patients with MEFV polymorphisms. The other five patients continued to experience PR, although three patients achieved remission with medication. CONCLUSIONS: PR presenting with IH might be associated with gene polymorphisms responsible for autoinflammatory diseases; colchicine appears to be effective in these patients.Key Point⢠Palindromic rheumatism with intermittent hydrarthrosis might be associated with gene polymorphisms responsible for autoinflammatory diseases.
Asunto(s)
Artritis Reumatoide/genética , Hidrartrosis/genética , Polimorfismo Genético , Adulto , Antiinflamatorios no Esteroideos/uso terapéutico , Artritis Reumatoide/tratamiento farmacológico , Colchicina/uso terapéutico , Femenino , Predisposición Genética a la Enfermedad , Humanos , Hidrartrosis/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Mutación , Pirina/genética , Estudios RetrospectivosAsunto(s)
Antirreumáticos/uso terapéutico , Hidrartrosis/tratamiento farmacológico , Hidrartrosis/genética , Proteína Antagonista del Receptor de Interleucina 1/uso terapéutico , Péptidos y Proteínas Asociados a Receptores de Factores de Necrosis Tumoral/genética , Femenino , Humanos , Persona de Mediana Edad , MutaciónRESUMEN
A study was carried out to verify the efficacy of intra-articular orgotein in patients with different forms of hydrarthrosis of the knee. The results confirm the value of orgotein for the local treatment of osteoarthritic joint swellings. However in the presence of marked exudative synovitis processes (chronic primary polyarthritis), the use of orgotein is of limited value.
Asunto(s)
Antiinflamatorios/uso terapéutico , Hidrartrosis/tratamiento farmacológico , Articulación de la Rodilla , Metaloproteínas/uso terapéutico , Superóxido Dismutasa/uso terapéutico , Adulto , Antiinflamatorios/administración & dosificación , Artritis/complicaciones , Artritis/tratamiento farmacológico , Artritis/etiología , Artritis Reumatoide/complicaciones , Artritis Reumatoide/tratamiento farmacológico , Evaluación de Medicamentos , Femenino , Humanos , Hidrartrosis/etiología , Inyecciones Intraarticulares , Masculino , Metaloproteínas/administración & dosificación , Psoriasis/complicaciones , Superóxido Dismutasa/administración & dosificaciónRESUMEN
Fifty-three patients, 28 females and 25 males, aged from 21 to 68 years, affected with mono- and bilateral intermittent hydrarthrosis of the knee and of a non-inflammatory nature, were included in an open study. All of the knees involved were treated with intra-articular infiltrations with Rifamycin SV. The weekly dosage of Rifamycin SV was 500 mg; the average duration of treatment was 6 weeks. Follow-up 1 year after the end of treatment showed a decrease or regression in joint effusion in all of the knees treated.
Asunto(s)
Hidrartrosis/tratamiento farmacológico , Articulación de la Rodilla , Rifamicinas/administración & dosificación , Adulto , Anciano , Femenino , Estudios de Seguimiento , Humanos , Hidrartrosis/etiología , Inyecciones Intraarticulares , Masculino , Persona de Mediana EdadAsunto(s)
Artritis Reumatoide/tratamiento farmacológico , Dexametasona/uso terapéutico , Eritema Nudoso/tratamiento farmacológico , Hidrartrosis/tratamiento farmacológico , Hidroxocobalamina/uso terapéutico , Osteoartritis/tratamiento farmacológico , Periartritis/tratamiento farmacológico , Adulto , Anciano , Femenino , Humanos , Articulación de la Rodilla , Masculino , Persona de Mediana Edad , Articulación del HombroAsunto(s)
Artritis Reumatoide/tratamiento farmacológico , Hidrartrosis/tratamiento farmacológico , Indometacina/uso terapéutico , Osteoartritis/tratamiento farmacológico , Esclerodermia Sistémica/tratamiento farmacológico , Espondilitis Anquilosante/tratamiento farmacológico , Tromboflebitis/tratamiento farmacológico , Adulto , Anciano , Femenino , Humanos , Persona de Mediana EdadAsunto(s)
Flumetasona/administración & dosificación , Enfermedades de los Caballos/tratamiento farmacológico , Artropatías/veterinaria , Animales , Artritis/tratamiento farmacológico , Artritis/patología , Artritis/veterinaria , Recuento de Células Sanguíneas , Glucemia/análisis , Proteínas Sanguíneas/análisis , Tolerancia a Medicamentos , Miembro Posterior , Enfermedades de los Caballos/diagnóstico por imagen , Enfermedades de los Caballos/patología , Caballos , Hidrartrosis/tratamiento farmacológico , Hidrartrosis/veterinaria , Inyecciones Intraarticulares , Artropatías/diagnóstico por imagen , Artropatías/tratamiento farmacológico , Radiografía , Líquido Sinovial/análisisAsunto(s)
Enfermedades de los Caballos/tratamiento farmacológico , Hidrartrosis/veterinaria , Hidroxiprogesteronas/administración & dosificación , Hidroxiesteroide Deshidrogenasas/metabolismo , Inflamación/tratamiento farmacológico , Articulaciones Tarsianas , Fosfatasa Ácida/sangre , Alanina Transaminasa/análisis , Fosfatasa Alcalina/sangre , Animales , Aspartato Aminotransferasas/análisis , Glucemia/análisis , Proteínas Sanguíneas/análisis , Femenino , Fructosa-Bifosfato Aldolasa/sangre , Hematócrito , Hemoglobinometría , Caballos , Hialuronoglucosaminidasa/farmacología , Hidrartrosis/tratamiento farmacológico , L-Lactato Deshidrogenasa/sangre , Masculino , Líquido Sinovial/análisisAsunto(s)
Artritis/veterinaria , Betametasona/uso terapéutico , Enfermedades de los Caballos/tratamiento farmacológico , Artropatías/veterinaria , Acetatos/uso terapéutico , Animales , Artritis/tratamiento farmacológico , Recuento de Células Sanguíneas , Glucemia/análisis , Femenino , Enfermedades de los Caballos/diagnóstico por imagen , Caballos , Hidrartrosis/tratamiento farmacológico , Inyecciones Intraarticulares/veterinaria , Artropatías/diagnóstico por imagen , Masculino , Osteoartritis/tratamiento farmacológico , Osteocondritis/diagnóstico por imagen , Osteocondritis/tratamiento farmacológico , Fosfatos/uso terapéutico , Radiografía , Líquido Sinovial/análisisAsunto(s)
Enfermedades de los Caballos/tratamiento farmacológico , Hidrartrosis/veterinaria , Metilprednisolona/uso terapéutico , Articulaciones Tarsianas , Fosfatasa Ácida/análisis , Alanina Transaminasa/análisis , Fosfatasa Alcalina/análisis , Animales , Aspartato Aminotransferasas/análisis , Glucemia/análisis , Proteínas Sanguíneas/análisis , Determinación del Volumen Sanguíneo , Pruebas Enzimáticas Clínicas , Femenino , Fructosa-Bifosfato Aldolasa/análisis , Hemoglobinometría , Caballos , Hidrartrosis/tratamiento farmacológico , Inyecciones Intraarticulares/veterinaria , L-Lactato Deshidrogenasa/análisis , Recuento de Leucocitos , Masculino , Líquido Sinovial/enzimologíaAsunto(s)
Enfermedades de los Bovinos/tratamiento farmacológico , Glucocorticoides/administración & dosificación , Hidrartrosis/veterinaria , Articulaciones Tarsianas , Alanina Transaminasa/análisis , Albúminas/análisis , Fosfatasa Alcalina/análisis , Animales , Aspartato Aminotransferasas/análisis , Bovinos , Femenino , Fructosa-Bifosfato Aldolasa/análisis , Globulinas/análisis , Glucosa/análisis , Hidrartrosis/tratamiento farmacológico , Hidroxiprogesteronas/administración & dosificación , Inyecciones Intraarticulares , L-Lactato Deshidrogenasa/análisis , Masculino , Metilprednisolona/administración & dosificación , Prednisolona/administración & dosificación , Líquido Sinovial/análisisAsunto(s)
Contractura/tratamiento farmacológico , Fracturas Óseas/tratamiento farmacológico , Hidrartrosis/tratamiento farmacológico , Desplazamiento del Disco Intervertebral/tratamiento farmacológico , Pirazoles/uso terapéutico , Traumatismos de los Tendones/tratamiento farmacológico , Heridas y Lesiones/tratamiento farmacológico , Adolescente , Adulto , Anciano , Antiinflamatorios/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
Samples of blood and joint fluid, from sixty patients who had taken Bufferin, were examined for salicylates. The earliest appreance of salicylates occurred in blood between 3 and 13 minutes after intake, and in joint fluid between 11 and 36 minutes. The individual time lapse from the first appearance of salicylates in blood to that in joint fluid, designated the transport time, varied presumably with the changes of the synovial membrane caused by diseases; it was small in synovitis following trauma or focal infection and in osteoarthritis of short duration; it was greater in osteoarthritis, psoriatic arthritis, and rheumatoid arthritis of longer duration, and it showed great variations in immediate traumatic synovitis. Salicylates attained maximum concentration in joint fluid 100 to 155 minutes after intake. Similar factors as above probably accounted for the differences in these time intervals.